Torrent Pharmaceuticals share news, announcements and annual reports
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,613.40up ₹33.40 (0.73%)BSE ₹4,635.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹4,580.00.
30 Oct: open ₹4,560.00, high ₹4,672.00, low ₹4,532.00
52-week range of traded prices to 30 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,75,479 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 82.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.82%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,36,64564.6% delivered
Torrent Pharmaceuticals share news and announcements
865 announcements, routine notices left out, newest first. Page 16 of 18.
May 2013
31 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2013 has recommended an additional dividend of Rs. 7/- per equity share of Rs. 5/- each fully paid up further to the interim dividend of Rs. 6/- per equity share. Also commemorating four decades of its business operations, the Board has also recommended a special dividend of Rs. 10/- per equity share. Considering this total dividend for the year becomes Rs. 23/- per equity share.31 May · Corporate action
Board of Directors of the Company at its meeting held on May 30, 2013 has recommended to issue bonus shares in the ratio of 1: 1 i.e. one equity bonus share for each fully paid up equity share. Consequent to the bonus issue, the total paid up share capital will be Rs. 84.62 crores from the existing Rs. 42.31 crores.14 May · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2013 and recommendation of dividend for the said year.
Apr 2013
Jan 2013
30 Jan · Dividend
Board of Directors of the Company at its meeting held on January 29, 2013, has declared an interim dividend of Rs. 6.00 per equity share of Rs. 5/- each fully paid up. These dividend amounts will be paid / dispatched on February 08, 2013.17 Jan · Corporate action
Company has fixed February 04, 2013 as the Record Date for the purpose of payment of Interim Dividend, if declared by the Board.17 Jan · Board meeting
To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2012. In the meeting, Board would also consider payment of Interim Dividend for the year 2012-13.
Oct 2012
26 Oct · Management
Board of Directors at their meeting held on October 26, 2012 has appointed Shri Pradeep Bhargava as Additional Director (Independent and Non-Executive) on the Board of the Company w.e.f. October 26, 2012.5 Oct · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the second quarter and half year ended on September 30, 2012.
Jul 2012
24 Jul · Disclosure of Voting Pattern - Clause 35A
24 Jul · Management
Changes in the directorate of the Company as approved by the Shareholders at their Annual General Meeting (AGM) held on July 23, 2012: (1) Shri Shashikant Bhojani has ceased to be a Director of the Company due to his retirement from the Board with effect from the conclusion of AGM above. (2) Dr. Leena Srivastava (who was earlier appointed as Additional Director by the Board of Directors at its meeting held on October 18, 2011) has been appointed as Director (Independent Non-Executive) of the Company w.e.f. July 23,2012, liable to retire by rotation; and (3) Mr Haigreve Khaitan (who was earlier appointed as Additional Director by the Board of Directors at its meeting held on January 23, 2012) has been appointed as Director (Independent Non-Executive) of the Company w.e.f. July 23, 2012, liable to retire by rotation.3 Jul · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the Quarter ended June 30, 2012.
May 2012
19 May · Corporate action
Share Transfer Books and Register of Members of the Company will remain closed from June 13, 2012 to June 15, 2012 (both days inclusive) for the purpose of deciding the name of shareholders entitled for final dividend for the year ended March 31, 2012, if declared by the Shareholders at the ensuing Annual General Meeting.19 May · Dividend
Board of Directors of the Company at its meeting held on May 18, 2012 has recommended a final dividend of Rs 2.50 per equity share of Rs.5/- each fully paid up. These dividend amounts, if declared by the Shareholders, are proposed to be paid / dispatched on or around July 27, 2012.4 May · Board meeting
To consider, inter alia, the Audited Financial Results for the year ended March 31, 2012 and recommendation of final dividend for the said year.
Jan 2012
24 Jan · Management
Board of Directors at their meeting held on January 23, 2012 has appointed Haigreve khaitan as Additional Director (Independent & Non-Executive) on the Board of the Company w.e.f. January 23, 2012.23 Jan · Dividend
Board of Directors of the company at its meeting held on January 23, 2012 has declared Interim Dividend @ Rs. 6 per equity share for the financial year 2011-12. The date of payment of dividend will be February 06, 2012.13 Jan · Corporate action
Company has fixed January 30, 2012 as the Record Date for the purpose of payment of Interim Dividend, if declared by the Board.13 Jan · Board meeting
To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2011. In the meeting, Board would also consider payment of Interim Dividend for the year 2011-12.
Oct 2011
19 Oct · Management
Board of Directors of the Company at its meeting held on October 18, 2011, inter alia, has approved the following changes in the directorate of the Company: (1) Dr. Chaitanya Dutt, has been re-appointed as Director (Research & Development) of the Company w.e.f. January 01, 2012 for a period of 3 years, subject to approval of the shareholders at their next General Meeting.(2) Dr. Leena Srivastava has been appointed as Additional Director of the Company w.e.f. October 18, 2011.(3) Renu Sud Karnad has ceased to be a Director of the Company w.e.f. October 10, 2011 due to her resignation.4 Oct · Board meeting
To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2011.
Aug 2011
1 Aug · Meeting
Jul 2011
15 Jul · Board meeting
To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis for the quarter ended June 30, 2011.
May 2011
30 May · Dividend
Board of Directors of the Company at its meeting held on May 28, 2011 has recommended a normal annual dividend of Rs.6.00 per equity share of Rs.5/- each fully paid up and a special dividend of Rs.2.00 per equity share of Rs.5/- each fully paid up. These dividend amounts, if declared by the Shareholders, are proposed to be paid/dispatched on August 03, 2011.19 May · Corporate action
Share Transfer Books and Registers of Members of the Company will remain close from June 08, 2011 to June 10, 2011 (both days inclusive) for the purpose of Dividend entitlement for the year 2010-11.12 May · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2011 and recommendation of dividend for the financial year 2010-11.
Apr 2011
29 Apr · Results
Company is exercising the option to submit audited financial results for the financial year ended March 31, 2011.
Mar 2011
30 Mar · News Verification
News Verification : The media had reports that Torrent Pharmaceuticals Limited may sell stake to London based AstraZeneca. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Torrent Pharmaceuticals Limited has vide its letter inter-alia stated, "We would like to inform you that the news item is absolutely baseless and untrue and the management denies the same. Further, there is no move on the part of the promoters of the Company or its management to sell any stake in the Company to any players, national or global."
Jan 2011
4 Jan · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and nine months ended on December 31, 2010.
Oct 2010
25 Oct · Management
Following changes have take place in the directors of the Company with immediate effect, as taken up by the Board in its meeting held on October 23, 2010:(1) Acceptance of the resignation of Kiran Karnik as Director of the Company.(2) Appointment of Shailesh V. Haribhakti as an additional director on the Board.7 Oct · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2010.